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Background
Several tumor markers may predict survival in HIV+
patients with diffuse large B-cell lymphoma (DLBCL).
Here, we evaluate the association of immunodeficiency
(CD4<200) on expression of prognostic tumor markers
and survival.
Methods
HIV+ DLBCL cases diagnosed between 1996-2007 within
Kaiser Permanente California were identified. H&E slides
were reviewed to identify representative tumor blocks for
tissue microarray (TMA) construction. Immunohisto-
chemistry staining of TMA cores was used to detect the
expression of selected markers in the categories of (1) cell
cycle regulators, (2) B-cell activators, (3) anti-apoptotic
proteins, and (4) others, including Epstein Barr Virus
(EBV). Percent of DLBCL cells with visible marker staining
was scored on a scale from 0-4 (i.e., 0-9%, 10-24%, 25-49%,
50-74% and ≥75%). EBV infection was determined by in
situ hybridization of EBV RNA. We also considered high
vs. low expression levels based on previously established
cut-offs. Of the 20 markers previously examined, three
had emerged as significant predictors of survival, including
EBV, cMYC and BLIMP1. Here, we evaluated the associa-
tion between CD4 and expression of these three markers
by t-test for mean levels and chi-square for % high levels.
We also evaluated the combined effect of immunodefi-
ciency and marker expression on 2-year survival in unad-
justed Cox models.
Results
We identified 194 HIV+ DLBCL cases; 80 patients had
adequate tissue for the marker analyses. Of the three mar-
kers, only EBV was associated with CD4 level (Table 1).
Survival was lowest in cases with high levels of EBV or
cMYC in combination with low CD4 (Table 2). Survival
was not evaluated for BLIMP1 given the low prevalence.
Conclusion
Immunodeficiency was associated with EBV+ DLBCL.
Cases with low CD4 and high levels of EBV or cMYC
had worse survival. Risk stratification may consider both
C D 4a n dt u m o rm a r k e re x p r e s s ion, although confirma-
tion is needed in larger studies.
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Table 1 Tumor marker levels by CD4
EBV cMYC BLIMP1
CD4 CD4 CD4
<200 ≥200 P <200 ≥200 P <200 ≥200 P
Mean levels 1.9 0.6 0.009 1.6 1.7 0.90 0.3 0.2 0.65
% high
levels
45.7 16.0 0.016 68.6 64.0 0.71 11.1 8.0 0.69
Table 2 Two-year survival by CD4 and marker levels
EBV cMYC
HR 95% CI P HR 95% CI P
Low CD4/high marker 4.0 1.6-10.2 0.004 3.3 1.0-11.5 0.057
Low CD4/low marker 1.8 0.7-4.9 0.236 1.0 0.2-4.8 0.970
High CD4/high marker 1.6 0.3-7.7 0.557 1.3 0.3-5.1 0.739
High CD4/low marker (ref) 1.0 - - 1.0 - -
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